...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Advanced drug delivery reviews >Inhaled formulations and pulmonary drug delivery systems for respiratory infections
【24h】

Inhaled formulations and pulmonary drug delivery systems for respiratory infections

机译：呼吸道感染的吸入制剂和肺部药物输送系统

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Respiratory infections represent a major global health problem. They are often treated by parenteral administrations of antimicrobials. Unfortunately, systemic therapies of high-dose antimicrobials can lead to severe adverse effects and this calls for a need to develop inhaled formulations that enable targeted drug delivery to the airways with minimal systemic drug exposure. Recent technological advances facilitate the development of inhaled anti-microbial therapies. The newer mesh nebulisers have achieved minimal drug residue, higher aerosolisation efficiencies and rapid administration compared to traditional jet nebulisers. Novel particle engineering and intelligent device design also make dry powder inhalers appealing for the delivery of high-dose antibiotics. In view of the fact that no new antibiotic entities against multi-drug resistant bacteria have come close to commercialisation, advanced formulation strategies are in high demand for combating respiratory 'super bugs'. (C) 2014 Elsevier B.V. All rights reserved.
机译：呼吸道感染是全球主要的健康问题。它们通常通过肠胃外施用抗微生物剂来治疗。不幸的是，高剂量抗微生物剂的全身疗法可能导致严重的不良反应，这要求开发吸入制剂，以使靶向药物以最小的全身性药物暴露量向气道输送。最近的技术进步促进了吸入抗微生物疗法的发展。与传统的喷射雾化器相比，新型网状雾化器实现了最小的药物残留，更高的雾化效率和更快的给药速度。新颖的颗粒工程和智能设备设计也使干粉吸入器吸引了大剂量抗生素的输送。鉴于没有针对多药耐药细菌的新型抗生素实体已接近商业化的事实，因此亟需先进的制剂策略来对抗呼吸道“超级臭虫”。 （C）2014 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号